This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: prolonged-release nicotinic acid

July 2008 Br J Cardiol 2008;15:210-14

Clinical experience with prolonged-release nicotinic acid in statin-treated patients managed in Ireland

Michael O’Reilly, Ulrike Hostalek, John Kastelein

Abstract

Introduction Cardiovascular events remain the leading cause of morbidity and mortality in developed countries, and the treatment of dyslipidaemia is central to the overall management of cardiovascular risk.1,2Although correction of hypercholesterolaemia remains the principal target for correction of the lipid profile, dyslipidaemia is heterogeneous in presentation, with many patients presenting with low high-density lipoprotein-cholesterol (HDL-C) in addition to elevated concentrations of ApoB-containing lipoproteins. A survey carried out in 11 European countries identified low HDL-C (<1.03 mmol/L in men and <1.29 mmol/L in women) in ab

| Full text

July 2006 Br J Cardiol 2006;13:278-82

Safety and tolerability of prolonged-release nicotinic acid in patients aged > 65 years enrolled in NAUTILUS

Anja Vogt, Ursula Kassner, Ulrike Hostalek, Elisabeth Steinhagen-Thiessen, on behalf of the NAUTILUS Study Group

Abstract

No content available

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now